A new avenue for treating neuronal diseases: Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects

doi:10.1016/j.bbr.2019.02.020

中山醫學大學機構典藏 CSMUIR > 醫學科技學院 > 心理學系暨臨床心理學暨碩士班 > 期刊論文 > Item 310902500/19903

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/19903

Title:	A new avenue for treating neuronal diseases: Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects
Authors:	Chen, A.-C. Lin, C.-L. Li, H.-H. Lin, P.-J. Liao, W.-C.
Contributors:	圖書館
Date:	2019-03
Issue Date:	2019-03-12T03:45:33Z (UTC)
ISSN:	01664328
Abstract:	Several neurodegenerative disorders, namely Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease, share common pathophysiological features, such as (1) cognitive deficits, (2) glutamatergic hyperactivity-related excitotoxicity, and (3) deposition of α-synuclein (α-syn) and β-amyloid (Aβ). Ceftriaxone (CEF) is a well-tested and safe drug that has been used as an antibiotic for several decades. Recent studies have demonstrated the following effects of CEF: (1) increasing glutamate transporter-1 expression and glutamate reuptake and suppressing excitotoxicity, (2) binding well with α-syn and inhibition of α-syn polymerization, (3) modulating expression of genes related to Aβ metabolism, and (4) enhancing neurogenesis and recovery of neuronal density. In addition, our data revealed that CEF ameliorates seizure and abnormal neuronal firing in the brain. These results suggest the potential of CEF in treating neuronal disorders. This paper addresses the effects and pharmacology of CEF. © 2019 Elsevier B.V.
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/19903
Relation:	Behavioural Brain Research Volume 364, 17 May 2019, Pages 149-156
Appears in Collections:	[心理學系暨臨床心理學暨碩士班] 期刊論文

Files in This Item:

File	Description	Size	Format
A-new-avenue-for-treating-neuronal-diseases-Ceftriaxone-an-old-antibiotic-demonstrating-behavioral-neuronal-effects2019Behavioural-Brain-Research.pdf		1038Kb	Adobe PDF	237	View/Open

View Licence

Loading...